Brief: Springworks Therapeutics Announces FDA Approval Of Gomekli (Mirdametinib) For Treatment Of Adult And Pediatric Patients With NF1-PN
11/02/2025 22:48
Feb 11 (Reuters) - SpringWorks Therapeutics Inc
SWTX.O :
* SPRINGWORKS THERAPEUTICS ANNOUNCES FDA APPROVAL OF
GOMEKLI™
(MIRDAMETINIB) FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS
WITH NF1-PN
Source text: ID:nGNX2JBPk7
Further company coverage: SWTX.O
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN